Feline Vaccines Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Feline Vaccines Market 

5.1. COVID-19 Landscape: Feline Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Feline Vaccines Market, By Vaccine Type

8.1. Feline Vaccines Market Revenue and Volume, by Vaccine Type

8.1.1. Inactivated (Killed) Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Live Attenuated Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Recombinant Vaccines

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Feline Vaccines Market, By Disease Type

9.1. Feline Vaccines Market Revenue and Volume, by Disease Type

9.1.1. Feline Panleukopenia Virus (FPV)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Feline Calicivirus (FCV)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Feline Herpesvirus Type 1 (FHV-1)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4.   Feline Leukemia Virus (FeLV)

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Rabies

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Feline Immunodeficiency Virus (FIV)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Feline Vaccines Market, By Technology 

10.1. Feline Vaccines Market Revenue and Volume, by Technology

10.1.1. Live Attenuated

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Inactivated

10.1.2.1. Market Revenue and Volume Forecast

10.1.3.   Recombinant DNA

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Subunit

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Toxoid

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Feline Vaccines Market, By Route of Administration

11.1. Feline Vaccines Market Revenue and Volume, by Route of Administration

11.1.1. Injectable Vaccines

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Intranasal Vaccines

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Oral Vaccines

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Feline Vaccines Market, By End-User

12.1. Feline Vaccines Market Revenue and Volume, by End-User

12.1.1. Veterinary Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2.   Veterinary Clinics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Animal Research Institutes

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Feline Vaccines Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.2. Market Revenue and Volume Forecast, by Disease Type

13.1.3. Market Revenue and Volume Forecast, by Technology

13.1.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.5. Market Revenue and Volume Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.6.2. Market Revenue and Volume Forecast, by Disease Type

13.1.6.3. Market Revenue and Volume Forecast, by Technology

13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.5. Market Revenue and Volume Forecast, by End-User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Vaccine Type

13.1.7.2. Market Revenue and Volume Forecast, by Disease Type

13.1.7.3. Market Revenue and Volume Forecast, by Technology

13.1.7.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.5. Market Revenue and Volume Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.2. Market Revenue and Volume Forecast, by Disease Type

13.2.3. Market Revenue and Volume Forecast, by Technology

13.2.4. Market Revenue and Volume Forecast, by Route of Administration  

13.2.5. Market Revenue and Volume Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.6.2. Market Revenue and Volume Forecast, by Disease Type

13.2.6.3. Market Revenue and Volume Forecast, by Technology

13.2.7. Market Revenue and Volume Forecast, by Route of Administration  

13.2.8. Market Revenue and Volume Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.9.2. Market Revenue and Volume Forecast, by Disease Type

13.2.9.3. Market Revenue and Volume Forecast, by Technology

13.2.10. Market Revenue and Volume Forecast, by Route of Administration

13.2.11. Market Revenue and Volume Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.12.2. Market Revenue and Volume Forecast, by Disease Type

13.2.12.3. Market Revenue and Volume Forecast, by Technology

13.2.12.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.13. Market Revenue and Volume Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Vaccine Type

13.2.14.2. Market Revenue and Volume Forecast, by Disease Type

13.2.14.3. Market Revenue and Volume Forecast, by Technology

13.2.14.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.15. Market Revenue and Volume Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.2. Market Revenue and Volume Forecast, by Disease Type

13.3.3. Market Revenue and Volume Forecast, by Technology

13.3.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.5. Market Revenue and Volume Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.6.2. Market Revenue and Volume Forecast, by Disease Type

13.3.6.3. Market Revenue and Volume Forecast, by Technology

13.3.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.7. Market Revenue and Volume Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.8.2. Market Revenue and Volume Forecast, by Disease Type

13.3.8.3. Market Revenue and Volume Forecast, by Technology

13.3.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.9. Market Revenue and Volume Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.10.2. Market Revenue and Volume Forecast, by Disease Type

13.3.10.3. Market Revenue and Volume Forecast, by Technology

13.3.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.5. Market Revenue and Volume Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Vaccine Type

13.3.11.2. Market Revenue and Volume Forecast, by Disease Type

13.3.11.3. Market Revenue and Volume Forecast, by Technology

13.3.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.5. Market Revenue and Volume Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.2. Market Revenue and Volume Forecast, by Disease Type

13.4.3. Market Revenue and Volume Forecast, by Technology

13.4.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.5. Market Revenue and Volume Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.6.2. Market Revenue and Volume Forecast, by Disease Type

13.4.6.3. Market Revenue and Volume Forecast, by Technology

13.4.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.7. Market Revenue and Volume Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.8.2. Market Revenue and Volume Forecast, by Disease Type

13.4.8.3. Market Revenue and Volume Forecast, by Technology

13.4.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.9. Market Revenue and Volume Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.10.2. Market Revenue and Volume Forecast, by Disease Type

13.4.10.3. Market Revenue and Volume Forecast, by Technology

13.4.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.5. Market Revenue and Volume Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Vaccine Type

13.4.11.2. Market Revenue and Volume Forecast, by Disease Type

13.4.11.3. Market Revenue and Volume Forecast, by Technology

13.4.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.5. Market Revenue and Volume Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.2. Market Revenue and Volume Forecast, by Disease Type

13.5.3. Market Revenue and Volume Forecast, by Technology

13.5.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.5. Market Revenue and Volume Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.6.2. Market Revenue and Volume Forecast, by Disease Type

13.5.6.3. Market Revenue and Volume Forecast, by Technology

13.5.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.7. Market Revenue and Volume Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Vaccine Type

13.5.8.2. Market Revenue and Volume Forecast, by Disease Type

13.5.8.3. Market Revenue and Volume Forecast, by Technology

13.5.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.5. Market Revenue and Volume Forecast, by End-User

Chapter 14. Company Profiles

14.1. Bimeda Holdings PLC

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Bioveta, a.s.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. HIPRA S.A.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Indian Immunologicals Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Vetoquinol S.A.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Zoetis Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Bimeda Holdings PLC

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Neogen Corporation

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Bayer Animal Health (now part of Elanco)

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Huvepharma EOOD

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms